About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 40886 record(s)
Req # A-2020-000513
Adverse Reaction Reports (AERs) for DOCETAXEL. Report numbers: 735515, 736109, E2B_02874263, E2B_02874284, E2B_02874482, E2B_02874490, E2B_02874501, E2B_02827637, E2B_02874508, E2B_02594947.Organization: Health Canada
January 2021
Req # A-2020-000547
Adverse Reaction Reports (AERs). Report numbers: E2B_02620725, E2B_02817496, E2B_02775725, E2B_02160205, E2B_02839703, E2B_01741041, E2B_02197570, E2B_02186547, E2B_02136662, E2B_02547381.Organization: Health Canada
January 2021
Req # A-2020-000594
Adverse Reaction Reports (AER) for botulinum toxin. Report number: E2B_03145732.Organization: Health Canada
January 2021
Req # A-2020-000632
Adverse Reaction Reports (AERs). Report numbers: E2B_02118066, 000719315, 000719253, E2B_02140181, E2B_02187160, 000720600, E2B_02225222, E2B_02274414, E2B_02275934.Organization: Health Canada
January 2021
Req # A-2020-000646
Adverse Reaction Reports (AERs) for DEXILANT. Report numbers: E2B_03001390, E2B_03007028. ADR for DEXLANSOPRAZOLE: 000737824. ADRs for ENTYVIO: E2B_03031243, E2B_03046110, E2B_03046110, E2B_02992604. ADRs for IXAZOMIB: E2B_03024203, E2B_03038125…Organization: Health Canada
January 2021
Req # A-2020-000661
Adverse Reaction Reports (AERs) for ENTYVIO. Report numbers: E2B_03053792, E2B_03060896, E2B_03063086, E2B_03080431, E2B_03081014, E2B_03086213, E2B_03087012, E2B_03106451, E2B_03108406, E2B_03108809, E2B_03111496, E2B_03111502, E2B_03122662,…Organization: Health Canada
January 2021
Req # A-2020-000664
Adverse Reaction Reports (AERs) for ONDANSETRON. Report numbers: 000910652, E2B_03062611, E2B_03095023, E2B_03151460.Organization: Health Canada
January 2021
Req # A-2020-000671
Adverse Reaction Report (AER) for Hydromorphone Hydrochloride. Report number: E2B_03142674.Organization: Health Canada
January 2021
Req # A-2020-000718
Adverse Reaction Report (AER) for FACTOR VII. Report number: E2B_03132694. ADR for ADDERALL XR: 000911513. ADRs for Amphetamine aspartate monohydrate: E2B_03072094, E2B_03099019. ADR for INTUNIV XR: 000915872. ADRs for MEZAVANT: E2B_03009989,…Organization: Health Canada
January 2021
Req # A-2020-000725
Adverse Reaction Reports (AERs). Report numbers: 000736518, E2B_02863275, E2B_03179765, E2B_02326291, E2B_02666714, E2B_03203966 E2B_03185578, E2B_03179136.Organization: Health Canada
January 2021